Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHAMM R3 peptide vaccination pilot study in hematologic malignancies
ISRCTN32763606Phase 2Completed
- Sponsor
- University Hospital Ulm
- Start
- Nov 2004
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RHAMM R3 peptide, sargramostim and incomplete freund's adjuvant in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM), sponsored by University Hospital Ulm. Primary endpoint: Clinical response by disease-specific criteria. Started Nov 2004; status: completed.
02
Drugs
RHAMM R3 peptidesargramostimincomplete freund's adjuvant
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN32763606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN32763606.